Clinical Trials Directory

Trials / Completed

CompletedNCT02218190

Alvimopan and Ileus in PSF

A Randomized Trial of Alvimopan for the Reduction of Ileus After Long Posterior Spinal Fusion

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
31 (actual)
Sponsor
Washington University School of Medicine · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to determine with Alvimopan reduces the incidence of post operative ileus in patients who undergo posterior spinal fusion.

Detailed description

Posterior spinal fusion (PSF) is a common orthopaedic procedure associated with a high incidence of post-operative ileus (POI) and concomitant increased length of hospital stay (LOHS). POI is exacerbated by high dose opiate consumption often required by these patients post-operatively. We propose a randomized, double-blinded, placebo-controlled pilot trial studying the use of alvimopan, a peripherally-acting mu-opioid receptor antagonist known to reduce POI in bowel resection. We hypothesize that alvimopan will shorten POI in spine fusion patients without negatively affecting post-operative pain control. Treatment efficacy will be assessed by recording time to first bowel movement, time to hospital discharge, and post-operative pain control. We hypothesize that acute administration of alvimopan, a peripherally-acting mu-opioid antagonist, shortens the duration of post-operative ileus (POI) in patients undergoing long-segment (5 or greater thoracolumbar levels) posterior spinal fusion (PSF). The study will be a randomized, double-blinded, placebo-controlled pilot trial. Reducing the morbidity of POI in patients undergoing PSF will decrease hospital stay and costs, and also improve patient satisfaction and post-operative care after major orthopaedic surgery.

Conditions

Interventions

TypeNameDescription
DRUGAlvimopan
DRUGPlacebo

Timeline

Start date
2014-08-01
Primary completion
2016-01-01
Completion
2019-01-01
First posted
2014-08-18
Last updated
2019-05-17
Results posted
2019-05-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02218190. Inclusion in this directory is not an endorsement.